These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32623916)

  • 1. Anti-HIV Activity of Standard Combined Antiretroviral Therapy in Primary Cells Is Intensified by CCR5-Targeting Drugs.
    Weichseldorfer M; Affram Y; Heredia A; Tagaya Y; Benedetti F; Zella D; Reitz M; Romerio F; Latinovic OS
    AIDS Res Hum Retroviruses; 2020 Oct; 36(10):835-841. PubMed ID: 32623916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of Active HIV-1 Infection in CD34
    Latinovic OS; Neal LM; Tagaya Y; Heredia A; Medina-Moreno S; Zapata JC; Reitz M; Bryant J; Redfield RR
    AIDS Res Hum Retroviruses; 2019 Aug; 35(8):718-728. PubMed ID: 31099257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
    van Lelyveld SF; Drylewicz J; Krikke M; Veel EM; Otto SA; Richter C; Soetekouw R; Prins JM; Brinkman K; Mulder JW; Kroon F; Middel A; Symons J; Wensing AM; Nijhuis M; Borghans JA; Tesselaar K; Hoepelman AI;
    PLoS One; 2015; 10(7):e0132430. PubMed ID: 26208341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.
    Chaillon A; Gianella S; Lada SM; Perez-Santiago J; Jordan P; Ignacio C; Karris M; Richman DD; Mehta SR; Little SJ; Wertheim JO; Smith DM
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
    Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
    Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).
    Ndhlovu LC; Umaki T; Chew GM; Chow DC; Agsalda M; Kallianpur KJ; Paul R; Zhang G; Ho E; Hanks N; Nakamoto B; Shiramizu BT; Shikuma CM
    J Neurovirol; 2014 Dec; 20(6):571-82. PubMed ID: 25227930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
    Bredeek UF; Harbour MJ
    Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
    Puertas MC; Massanella M; Llibre JM; Ballestero M; Buzon MJ; Ouchi D; Esteve A; Boix J; Manzardo C; Miró JM; Gatell JM; Clotet B; Blanco J; Martinez-Picado J;
    AIDS; 2014 Jan; 28(3):325-34. PubMed ID: 24185044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maraviroc: a new CCR5 antagonist.
    Sayana S; Khanlou H
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined cART including Tenofovir Disoproxil, Emtricitabine, and Dolutegravir has potent therapeutic effects in HIV-1 infected humanized mice.
    Weichseldorfer M; Affram Y; Heredia A; Rikhtegaran-Tehrani Z; Sajadi MM; Williams SP; Tagaya Y; Benedetti F; Ramadhani HO; Denaro F; Munawwar A; Bryant J; Zella D; Reitz M; Romerio F; Latinovic OS
    J Transl Med; 2021 Oct; 19(1):453. PubMed ID: 34717655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study.
    Cuzin L; Trabelsi S; Delobel P; Barbuat C; Reynes J; Allavena C; Peytavin G; Ghosn J; Lascoux-Combe C; Psomas C; Corbeau P; Flandre P;
    J Acquir Immune Defic Syndr; 2012 Dec; 61(5):557-64. PubMed ID: 22986949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.
    Ishizaka A; Sato H; Nakamura H; Koga M; Kikuchi T; Hosoya N; Koibuchi T; Nomoto A; Kawana-Tachikawa A; Mizutani T
    J Virol; 2016 Jun; 90(12):5665-5676. PubMed ID: 27030274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.
    Ruiz L; Martinez-Picado J; Romeu J; Paredes R; Zayat MK; Marfil S; Negredo E; Sirera G; Tural C; Clotet B
    AIDS; 2000 Mar; 14(4):397-403. PubMed ID: 10770542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicted coreceptor usage at end-stage HIV disease in tissues derived from subjects on antiretroviral therapy with an undetectable plasma viral load.
    Lamers SL; Fogel GB; Liu ES; Nolan DJ; Salemi M; Barbier AE; Rose R; Singer EJ; McGrath MS
    Infect Genet Evol; 2017 Jul; 51():194-197. PubMed ID: 28392467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral T Follicular Helper Cells Are the Major HIV Reservoir within Central Memory CD4 T Cells in Peripheral Blood from Chronically HIV-Infected Individuals on Combination Antiretroviral Therapy.
    Pallikkuth S; Sharkey M; Babic DZ; Gupta S; Stone GW; Fischl MA; Stevenson M; Pahwa S
    J Virol; 2015 Dec; 90(6):2718-28. PubMed ID: 26676775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.
    Chéret A; Nembot G; Mélard A; Lascoux C; Slama L; Miailhes P; Yeni P; Abel S; Avettand-Fenoel V; Venet A; Chaix ML; Molina JM; Katlama C; Goujard C; Tamalet C; Raffi F; Lafeuillade A; Reynes J; Ravaux I; Hoën B; Delfraissy JF; Meyer L; Rouzioux C;
    Lancet Infect Dis; 2015 Apr; 15(4):387-96. PubMed ID: 25701561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound.
    López-Huertas MR; Gutiérrez C; Madrid-Elena N; Hernández-Novoa B; Olalla-Sierra J; Plana M; Delgado R; Rubio R; Muñoz-Fernández MÁ; Moreno S
    Sci Rep; 2020 Dec; 10(1):22286. PubMed ID: 33339855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.